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A B S T R A C T
Background: Acute kidney injury (AKI) after cardiac surgery is associated with increased mortality, but
few data exist on the occurrence and clinical impact of AKI associated with transcatheter aortic valve
implantation (TAVI). The objective of this study was to determine the incidence and prognosis of AKI
after percutaneous implantation of the CoreValve1 (Medtronic, Minneapolis, MN, USA) prosthesis.
Methods: A total of 357 patients with severe aortic stenosis and 9 patients with pure native aortic
regurgitation were treated with the CoreValve prosthesis. AKI was deﬁned according to Valve Academic
Research Consortium criteria as the absolute increase in serum creatinine 0.3 mg/dl at 72 h post
percutaneous procedure.
Results: AKI was identiﬁed in 58 patients (15.8%), none of whom required renal replacement therapy. In
patients with AKI, the mortality at 30 days was 13.5% compared with 1.6% of patients without AKI, [odds
ratio (OR) = 12.2 (95% CI 3.53–41.9); p < 0.001] and total mortality after a mean of 26.2  17 months was
29.3% vs. 14.9% [OR = 2.36 (95% CI 1.23–4.51), p = 0.008]. In the multivariate analysis, AKI was an
independent predictor of cumulative total mortality [hazard ratio = 2.151, (95% CI from 1.169 to 3.957),
p = 0.014].
Conclusions: The deterioration of renal function in patients undergoing TAVI with the CoreValve
prosthesis is a serious and frequent complication. The occurrence of AKI was associated with increased
early mortality and was also a predictor of worse outcomes in follow-up.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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The incidence of acute kidney injury (AKI) is a serious
complication in patients with severe aortic stenosis undergoing
valve replacement surgery, with an incidence between 1% and 30%,
depending on the deﬁnition used [1]. In addition, it is associated
with high mortality [2]. AKI can occur in different clinical
scenarios, such as transcatheter aortic valve implantation (TAVI),
which has become an alternative therapeutic option for patients
with severe aortic stenosis considered at high surgical risk* Corresponding author at: Department of Cardiology Hospital Clı´nico
Universitario Virgen de la Victoria, Campus de Teatinos s/n, 29010 Ma´laga,
Spain. Tel.: +34 952300525; fax: +34 952300525.
E-mail address: ajmunozgarcia@secardiologia.es (A.J. Mun˜oz-Garcı´a).
http://dx.doi.org/10.1016/j.jjcc.2014.09.009
0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights[3,4]. Some studies suggest that TAVI is an effective and safe
method to treat kidney transplant recipients who have aortic
stenosis, and it is associated with lower morbidity and mortality
compared to conventional open-heart surgery [5]. However, few
data exist on the impact of AKI on clinical outcome.
The objective of this study was to determine the occurrence
and prognosis of AKI on short- and long-term outcomes after
percutaneous implantation of the CoreValve1 (Medtronic,
Minneapolis, MN, USA) aortic valve prosthesis in patients with
aortic stenosis who are considered at high surgical risk.
Materials and methods
Between April 2008 and December 2013, 363 patients with
symptomatic aortic valve stenosis and 9 patients with pure native
aortic valve regurgitation who were considered high-risk or reserved.
Table 1
Baseline and periprocedural characteristics of patients undergoing TAVI, according
to the occurrence of post-procedural AKI.
Without AKI
N = 308
AKI N = 58 p value
Age (years) 79.2  6.4 79.9  4.5 0.444
Sex (male) 122 (39.6%) 28 (48.3%) 0.218
Cardiovascular risk factor
Hypertension 254 (82.5%) 47 (84%) 0.793
Diabetes mellitus 133 (43.2%) 17 (29.3%) 0.058
Hyperlipidemia 160 (51.9%) 29 (50%) 0.785
Smoker 73 (23.7%) 14 (24.1%) 0.943
Coronary artery disease 121 (39.3%) 26 (44.8%) 0.430
Acute myocardial infarction 52 (16.9%) 7 (12.1%) 0.360
CABG 25 (8.1%) 7 (12.1%) 0.328
PCI 87 (28.2%) 16 (27.6%) 0.918
Frailty, n (%) 49 (15.9%) 5 (8.6%) 0.151
Charlson index, mean  SD 3.4  1.8 3.6  2 0.517
Logistic EuroSCORE (%) 18  11 18.3  14 0.849
I. Karnofsky, mean  SD 60.2  19 62.7  19 0.364
Prior stroke 36 (11.7%) 16 (27.6%) 0.001
Porcelain aorta 23 (7.5%) 5 (8.6%) 0.762
Extracardiac arteriopathy 49 (16%) 12 (20.7%) 0.376
NYHA class functional III–IV 270 (87.7%) 49 (84.5%) 0.126
COPD 109 (35.4%) 20 (34.5%) 0.894
Pure native aortic
regurgitation
5 (1.6%) 4 (6.9%) 0.017
Pre-procedural creatinine
(mg/dl)
1.28  0.4 1.29  0.9 0.928
Glomerular ﬁltration rate 49.01  21 48.3  19.1 0.822
Chronic kidney disease stage 68 (22.1%) 14 (24.1%) 0.730
Echocardiographic parameters
LVEF (%), mean  SD 60.2  15 61.7  13.4 0.479
LVEF < 40% 55 (17.9%) 8 (13.8%) 0.452
Moderate or severe MR 67 (21.7%) 8 (13.7%) 0.239
Moderate or severe AR 116 (37.3%) 20 (34.5%) 0.868
Pulmonary hypertension 58 (20%) 8 (13.7%) 0.752
Treatment
Diuretics 281 (91.2%) 55 (94.8%) 0.360
Calcium antagonist 49 (15.9%) 9 (15.5%) 0.940
Beta-blockers 136 (44.3%) 28 (48.3%) 0.577
ACE inhibitors 180 (58.6%) 38 (65.5%) 0.327
Digoxin 33 (10.7%) 4 (6.9%) 0.373
Procedure
Time of procedure
(minutes)
101.5  36 109  44 0.130
Access site
Trans-femoral 277 (89.9%) 49 (84.5%)
Trans-subclavian 30 (9.7%) 8 (13.8%) 0.342
Direct trans-aortic 1 (0.3%) 1 (1.7%)
General anesthesia 26 (8.4%) 6 (10.3%) 0.638
Pre-dilatation 253 (84.3%) 47 (81%) 0.840
Prosthesis
23 mm 4 (1.3%) 1 (1.8%)
26 mm 186 (60.4%) 26 (45.6%) 0.128
29 mm 107 (34.7%) 29 (50.9%)
31 mm 11 (3.6%) 1 (1.8%)
Post-dilatation 83 (26.9%) 17 (29.3%) 0.711
Valve in valve 14 (4.5%) 5 (8.8%) 0.187
AR post-TAVI  2+ Sellers 73 (23.8%) 19 (32.8%) 0.028
New onset LBBB 100 (46.7%) 19 (51.4%) 0.607
Required pacemaker
implantation
71 (24.9%) 20 (37.7%) 0.053
Red blood cell transfusion 95 (32.4%) 19 (35.2%) 0.691
TAVI, transcatheter aortic valve implantation; AKI, acute kidney injury; NYHA,
New York Heart Association; COPD, chronic obstructive pulmonary disease;
CKD, chronic kidney disease; AR, aortic regurgitation; ACE, angiotensin-
converting enzyme; LVEF, left ventricular ejection fraction; MR, mitral
regurgitation; CABG, coronary artery bypass graft; PCI, percutaneous coronary
intervention; LBBB, Left Bundle Branch Block.
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eValve prosthesis. AKI was deﬁned according to the Valve
Academic Research Consortium (VARC) criteria [6], as the absolute
increase in serum creatinine 0.3 mg/dl or an increase of over 50%
at 72 h post-procedure.
From our analysis, we excluded two patients with preoperative
renal replacement therapy and four patients who died during
procedure due to left ventricular perforation, iatrogenic dissection
of left main coronary artery, electromechanical dissociation, or
cardiogenic shock prior to prosthesis implantation.
All patients underwent a systematic determination of serum
creatinine and an estimated glomerular ﬁltration rate (eGFR)
calculation based on the simpliﬁed modiﬁcation of diet in renal
disease (MDRD) formula 24 h prior to procedure, 72 h after TAVI,
and at 6 months following the procedure.
Chronic kidney disease (CKD) was deﬁned as an eGFR <60 mL/
min/1.73 m2, equivalent to CKD stage 3 according to the Kidney
Disease Outcome Quality Initiative [7].
We routinely used a prophylactic treatment with N-acetylcys-
teine, and patients with preprocedural CKD received intravenous
hydration before the procedure, for the prevention of contrast-
induced nephropathy. The contrast medium used in all TAVI
procedures was iodixanol 320 mg of iodine/ml (Visipaque, GE
Healthcare, Cork, Ireland), which is a non-ionic, iso-osmolar,
dimetric type of contrast medium.
Statistical analysis
The data are expressed as the mean  standard deviation for
continuous variables and as the absolute number and percentage for
categorical variables. A basic descriptive analysis and a survival
analysis were performed with the Kaplan–Meier method. Qualitative
variables were compared using the x2 or Fisher’s test, and the Student
t test was used for continuous variables according to their
distribution. A stepwise logistic regression analysis including
signiﬁcant variables in the univariate analysis was used to determine
independent predictors of AKI. Results are presented as odds ratio
(OR) with 95% conﬁdence intervals (CI). A multivariate analysis was
made with Cox regression analysis to identify the variables related
with late mortality and performed stepwise to show the association of
the various risk factors more clearly. This model included those
variables that were signiﬁcant (p < 0.05) in the univariate analysis.
Results are presented as a hazard ratio (HR) with 95% CI. Signiﬁcance
was set at p < 0.05. The data were analyzed with SPSS version 15.0
(Chicago, IL, USA).
Results
AKI was identiﬁed in 58 patients (15.8%), none of whom
required renal replacement therapy. After implantation there was
a slight improvement in renal function, baseline serum creatinine
decreased from 1.29  0.5 mg/dl to 1.20  0.5 mg/dl (p = 0.001),
eGFR increased from 48.9  20 mL/min/1.73 m2 to 52.7  22 mL/
min/1.73 m2 (p = 0.001) and remained stable at 6 months following
procedure (creatinine 1.21  0.4 mg/dl and eGFR 50.25  19 mL/min/
1.73 m2). There were no differences in the amount of contrast
medium received (176  64 cm3 for patients with AKI vs. 169
 67 cm3 for patients without AKI, p = 0.470). The serum creatinine
improved in patients with CKD, slightly decreasing from 1.96
 0.4 mg/dl to 1.74  0.5 mg/dl, p = 0.001, with an increase in eGFR
from 32.6  13 mL/min/1.73 m2 to 37.2  17 mL/min/1.73 m2. The
factors associated with the development of AKI are shown in Table 1
and the only independent predictors for AKI after TAVI were prior
stroke [OR 2.42, (95% CI 1.175–4.985), p = 0.017] and the presence of
pure native aortic regurgitation [OR 4.642 (95% CI 1.106–19.49),
p = 0.036].In patients with AKI, mortality at 30 days was 13.8% compared
with 1.3% of patients without AKI, p = 0.001; total mortality after a
mean of 26.2  17 months was 29.3% in patients with AKI compared
with 14.9% in those without AKI, p = 0.008.
Fig. 1. Comparative analysis between survival in patients with and without AKI
after transcatheter aortic valve implantation (using Kaplan–Meier survival curves),
log-rank test = 7.89; p < 0.005. AKI, acute kidney injury; Cum, cumulative.
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in patients without AKI compared with 78.8% and 69.3% in patients
with AKI (Fig. 1).
In the multivariate analysis, AKI was an independent predictor
of cumulative total mortality (Table 2).
Discussion
In the present study, we show that the AKI group had higher
mortality at 30 days compared with the group without AKI and also
that AKI was a strong independent predictor of late mortality.
In our study, AKI, based on VARC deﬁnition, occurred in 15.8% of
patients undergoing TAVI, which is similar to percentages reported
by other series [8–10], but in our series no patient required renal
replacement therapy.
Khawaja et al. [11] reported that the incidence of AKI in a series
of 248 patients was 35.9%, with 10% requiring dialysis. This
different incidence reported is probably due to the different
baseline characteristics of the patients: 18.1% of patients were in
stage 4 or 5 of CKD and there are important differences based on
the approaches used to implant the prosthesis (43.1% trans-
femoral, 41.5% trans-apical, and 15.3% trans-aortic), compared
with our study (89.1% trans-femoral, 10.3% trans-subclavian, and
0.5% trans-aortic). Recently, Saia et al. [12] reported similar results:
the incidence of AKI was 41.7% and there were differences
according to the approaches used, so the trans-apical access might
have contributed to the higher rate of AKI in these studies.
Nevertheless, the mechanisms of renal damage after TAVI are
probably multifactorial, and the predictive factors of renal injuryTable 2
Multivariate and Cox regression analyses: independent factors of total mortality in
long-term follow-up after TAVI.
HR CI 95% p
Acute kidney injury 2.151 1.169–3.957 0.014
Stroke after TAVI 5.644 1.988–16.02 0.001
Coronary artery disease 2.473 1.453–4.209 0.001
Karnofsky index 0.975 0.961–0.988 0.001
TAVI, transcatheter aortic valve implantation; HR, hazard ratio; CI, conﬁdence
interval.after TAVI have not been well deﬁned; some studies identify
hypertension and chronic obstructive pulmonary disease as
signiﬁcant risk factors for AKI [8]. In our series only prior stroke
was associated with the development of AKI and it is likely that
these patients had more peripheral arterial disease, with a higher
risk of embolization of atheromatous plaques, than patients with
pure native aortic regurgitation; it is possible that the critical
clinical state of these patients pre-procedure inﬂuenced the renal
perfusion. The need for red blood cell transfusion is a well-
recognized predictor of AKI after TAVI and following cardiac
surgery in most series [8,9]. However, this was not conﬁrmed in
our study; it is possible that the effect of blood transfusion on the
development of AKI depends on the number of units used. In the
present study this was 1.8  2 units compared with 3.6  4.3 units in
the series where blood transfusion was a predictor of AKI [8].
An interesting ﬁnding of this study was that the number of
patients with aortic regurgitation AR post-TAVI > 2+ Sellers was
higher in the AKI group than in the group without AKI. In addition,
pure native aortic valve regurgitation is associated with an
increased risk of developing AKI after TAVI. This is an important
ﬁnding because AR is a strong independent predictor of mortality
in the TAVI population in most series [13–15]. Acute AR could be
associated with a negative impact on left ventricular function, due
to a lack of left ventricular dilatation that leads to a rapid rise of
end-diastolic pressure relative to regurgitant volume and a low
forward stroke volume, inﬂuencing renal perfusion. This increase
in end-diastolic pressure related to backward volume is even
greater in patients with aortic stenosis due to the presence of
diastolic dysfunction.
Another possible mechanism contributing to the development
of AKI is contrast nephropathy; however, we found that the
amount of contrast medium was not associated with AKI after
TAVI, probably due to prophylactic administration of oral
acetylcysteine as well as careful management of ﬂuids, particularly
in older patients with high preoperative serum creatinine, and the
use of iso-osmolar contrast media in all our patients undergoing
TAVI. Nevertheless, several previous investigations have identiﬁed
that a ratio of contrast media  serum creatinine/body weight over
2.7 is associated with an increased risk of AKI after TAVI; therefore,
the contrast dose should be adjusted [16].
Compared with other percutaneous procedures, a TAVI carries
an inherent risk of hemodynamic changes during procedure and an
increased risk of complications, such as vascular complications,
requiring red blood cell transfusion or residual paravalvular aortic
regurgitation, all of which may potentially increase the risk of AKI.
In the present study, when we analyzed the predictors of AKI in the
multivariate analysis, predictors were prior stroke and pure aortic
valve regurgitation. Thus, the risk of AKI after TAVI depends
primarily on patient clinical characteristics and, perhaps, on
procedure.
In order to prevent the occurrence of AKI, good screening and
appropriate patient selection are crucial, TAVI patients should
receive optimal hydration and total amount of contrast media
should be minimized, and the presence of aortic debris should be
assessed to avoid distal embolization [17].
Interestingly, there was a slight additional improvement in
renal function among most CKD patients, and it appears probable
that improvement in cardiac performance after TAVI leads to an
enhancement in renal function.
The results of the present study show that patients who
presented with AKI had a higher mortality at 30 days after TAVI and
conﬁrm AKI as an independent predictor of late mortality in long-
term follow-up. Bagur et al. [8] reported that AKI was an
independent predictor of in-hospital mortality after TAVI, which
is consistent with our data. Webb et al. [18] and the Italian registry
demonstrated that CKD was an important independent predictor
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highlight the important effect of renal function on the clinical
outcome of patients undergoing TAVI.
This study has some limitations: this was a single-center study
with inclusion criteria censored by a multidisciplinary team. The
results may therefore be inﬂuenced by the effects of possible
confounders and bias in the study design and selection. Results
were based on a single determination of serum creatinine and
eGFR at 72 h following procedure, whereas it has recently been
recommended that timing for diagnosis of AKI be extended from
72 h to 7 days. The role of an adjusted contrast dose was not
analyzed and dosage appears to be associated with contrast-
induced nephropathy.
Conclusions
The deterioration of renal function in patients undergoing TAVI
with the CoreValve prosthesis is a serious and frequent complica-
tion. The occurrence of AKI was associated with increased early
mortality and was also a predictor of worse outcomes in long-term
follow-up.
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